Heron Therapeutics Inc vs SpaceX — how do they compare? Heron Therapeutics Inc trades at $0.32 (market cap $61.47M), while SpaceX trades at $146.22 (market cap $1.76T). The key difference: SpaceX is far larger — about 28631.9× Heron Therapeutics Inc's market cap, and SpaceX is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| HRTX | SPCX | |
|---|---|---|
Market Cap | $61.47M | $1.76T |
Sector | Health | Technology |
52-Week High | $1.49 | $202.09 |
52-Week Low | $0.32 | $108.27 |
Enterprise Value | $168.21M | $1.70T |
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) trades at $0.3409, up 3.24% today, but faces bearish technical signals with 18 sell indicators versus 6 buys. The company reported Q2 2026 revenue of $37.7 million but missed earnings expectations with a $0.03 per share loss. Despite strong analyst support (94.7% buy ratings), fundamental challenges persist with negative net income margins and elevated EV/EBITDA of 34.03.
Investment outlook remains cautious due to consistent earnings misses and negative cash flow from operations. The primary opportunity lies in analyst optimism and potential product growth, while risks include ongoing profitability challenges and competitive pressures in the biotechnology sector.
SPCX stock trades at $146.22, up 5.39% today, buoyed by strong technical momentum and positive news flow. The stock shows bullish moving average signals and trades above key support levels. Recent Q2 earnings beat expectations, though the company remains unprofitable with a net income margin of -35.66%. High-profile institutional investments, including Norway's sovereign wealth fund, underscore growing confidence in SpaceX's AI and Starlink growth trajectory.
Outlook is optimistic given analyst consensus and AI-driven revenue potential, but risks include persistent losses, high valuation multiples, and insider share unlocks. The consensus price target of $228.52 implies significant upside if execution aligns with ambitious growth plans.
Trailing returns across standard periods
Latest headlines on both assets
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →SpaceX is the world's leading aerospace manufacturer and launch provider. It designs and operates reusable rockets, spacecraft, and Starlink, a global satellite internet service with over 10 million subscribers across 160 countries.
Read more on SPCX →